Innovative use of triphenylphosphine oxide from industrial waste shows promise for sustainable energy storage in redox flow batteries, researchers say.
Additionally, the Phase 1 clinical trial evaluating QTX3034, an oral G12D-preferring multi-KRAS inhibitor, as a monotherapy and in combination with cetuximab, continues to enroll patients, and data is ...